Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Medtronic
Harvard Business School
Mallinckrodt
McKinsey

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 212327

See Plans and Pricing

« Back to Dashboard

NDA 212327 describes INREBIC, which is a drug marketed by Impact and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the INREBIC profile page.

The generic ingredient in INREBIC is fedratinib hydrochloride. One supplier is listed for this compound. Additional details are available on the fedratinib hydrochloride profile page.
Summary for 212327
Tradename:INREBIC
Applicant:Impact
Ingredient:fedratinib hydrochloride
Patents:4
Generic Entry Opportunity Date for 212327
Generic Entry Date for 212327*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 212327
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
INREBIC fedratinib hydrochloride CAPSULE;ORAL 212327 NDA Celgene Corporation 59572-720 59572-720-12 120 CAPSULE in 1 BOTTLE, PLASTIC (59572-720-12)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 100MG BASE
Approval Date:Aug 16, 2019TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 16, 2024
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:  Start TrialPatent Expiration:May 29, 2032Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS
Patent:  Start TrialPatent Expiration:Dec 16, 2026Product Flag?Substance Flag?YDelist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Merck
Baxter
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.